| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00082563 Details | 2011-04-26 Interventional | 2 | 14 | Azithromycin Chloroquine Chloroquine dip… Malaria, Falcip… | - - | |||
| NCT01074359 Details | 2011-04-22 Interventional | 2 | - | Tocopherylquino… Neuromuscular D… Neuromuscular D… | Terminated for Commercial Reasons. There were no safety issues involved in the decision to
terminate the study. - | |||
| NCT00433017 Details | 2011-04-21 Interventional | 2/3 | 255 | Ranibizumab Verteporfin Choroidal Neova… Macular Degener… Neovascularizat… | Study was terminated based on the results of analyses performed as planned at Month 12. - | |||
| NCT00352651 Details | 2011-04-14 Interventional | 2 | - | Pregabalin Herpes Simplex Herpes Zoster Neuralgia Neuralgia, Post… Postherpetic Ne… | This study should be terminated as the study has been closed for years and the investigator has
since retired. No records are available.
Thank you, Marlene - | |||
| NCT00162214 Details | 2011-04-14 Interventional | 1 | - | Dasatinib Ketoconazole Neoplasms Tumors | - - | |||
| NCT01133873 Details | 2011-04-13 Interventional | 4 | - | Dextropropoxyph… Levopropoxyphen… Healthy | - - | |||
| NCT00979667 Details | 2011-04-11 Interventional | 3 | 4 | Oseltamivir Zanamivir Communicable Di… Infections Influenza, Huma… Orthomyxovirida… Respiratory Tra… Influenza Upper Respirato… | Decreased Influenza activity; thus decrease/no eligible patient to recruit - | |||
| NCT00534456 Details | 2011-04-08 Interventional | 3 | 12 | Darbepoetin alf… Anemia Cardiovascular … Heart Failure Ventricular Dys… Cardiovascular … Congestive Hear… | Study terminated - | |||
| NCT00353808 Details | 2011-04-07 Interventional | 2 | 112 | Reboxetine Pain | This study has been terminated early as the esreboxetine development program is being
discontinued. There are no safety or efficacy concerns. - | |||
| NCT00930358 Details | 2011-04-06 Interventional | 4 | 220 | Anesthetics Colonoscopy Pro… | This study was stopped due to low inclusion - | |||
| NCT01117376 Details | 2011-03-31 Interventional | 2 | - | Erythromycin Erythromycin Es… Erythromycin Et… Erythromycin st… Methylnaltrexon… Gastroparesis | The study was prematurely terminated because of unavailibility of Methylnaltrexone in the
region - | |||
| NCT00124709 Details | 2011-03-23 Interventional | 4 | 1091 | Pimecrolimus Dermatitis Dermatitis, Ato… Eczema Atopic Dermatit… | - - | |||
| NCT00785811 Details | 2011-03-16 Interventional | 4 | 36 | N-Methylasparta… Fatigue Muscular Fatigu… | Required by the investigator. The site could not recruit patients anymore. - | |||
| NCT00049959 Details | 2011-03-16 Interventional | 3 | - | Verteporfin Basal Cell Nevu… Carcinoma Carcinoma, Basa… Syndrome Basal Cell Carc… Gorlin Syndrome Nevoid Basal Ce… | - - | |||
| NCT00000659 Details | 2011-03-14 Interventional | 2 | - | Zidovudine AIDS-Related Co… HIV Infections | - - | |||
| NCT00540280 Details | 2011-03-08 Interventional | 3 | - | Gemcitabine Carcinoma, Non-… | Follow up only - | |||
| NCT00480103 Details | 2011-03-04 Interventional | 3 | - | Mineral Oil Healthy | INHERENT MODIFICATIONS NEEDED BEFORE PROCEEDING - | |||
| NCT00774878 2008-000810-54 Details | 2011-03-03 Interventional | 2 | 18 | Fulvestrant Breast Neoplasm… | Company decision to discontinue the AVE1642 development program, not due to any safety or
efficacy concerns - | |||
| NCT00514891 Details | 2011-03-01 Interventional | 4 | - | Vitamin A Morbidity Mortality | Reccomended by DSMB after review of planned interim analyses. - | |||
| NCT00316017 Details | 2011-03-01 Interventional | 3 | [1 Refs] | 895 | Dextrans Shock Shock, Traumati… Wounds and Inju… | Futility & potential safety concern (increased early mortality in the HS/HSD arms for those
with no PRBC in 1st 24 hr, post-randomization subgp) The trial was stopped early for futility in the presence of a potential safety concern regarding increased mortality among patients receiving hypertonic solutions and no blood transfusions. This was no longer evident 6 hr after hospital admission. |